Four questions, asked in this order, will tell you within ten minutes whether a Philadelphia provider is operating under federal compounding law or operating something to walk away from. The same diagnostic line of questioning used by patients evaluating practitioners across other large metropolitan medical markets applies here. In a state with Pennsylvania's depth of clinical infrastructure, the standard of evidence patients should expect is on the higher end.
1. Can the practitioner explain, in plain terms, why a peptide is being compounded under section 503A — and which pharmacy they work with?
A credible clinician articulates the regulatory rationale without marketing copy. Section 503A of the FDCA permits a licensed pharmacist to prepare a patient-specific compound when no commercially available equivalent meets the need. They should name the 503A pharmacy and discuss its Pennsylvania licensure and inspection history. Deflection on this question is itself the answer.
2. Will baseline labs — IGF-1, hormone panels, metabolic markers — be drawn before any peptide protocol begins?
Ask which baseline tests are appropriate for the specific treatment being considered and who reviews the results. A clinic should explain how its evaluation and monitoring plan relates to your medical history instead of treating every patient as if the same protocol fits.
3. What is the follow-up cadence — three months, six months — and who reviews the labs?
Anti-aging protocols are not one-and-done prescriptions. The physician, or a credentialed nurse practitioner under direct physician oversight, should review repeat labs at fixed checkpoints and adjust dose, frequency, or cessation based on what the numbers show. Ask who reviews the labs and how that review is documented in the chart.
4. What conditions would cause the physician to stop the protocol — and how is that decision made?
A practitioner who cannot describe their stop-criteria has not thought about them. Reasonable answers include out-of-range IGF-1, adverse event, lack of measurable improvement at a defined checkpoint, or any new contraindication identified during follow-up. If the answer reduces to "we just keep going," that is a position the patient — not the clinic — will eventually be asked to defend.